A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
restrict direct-to-consumer drug advertising. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Responsibility in Drug 
4
Advertising Act of 2019’’. 
5
SEC. 2. DIRECT-TO-CONSUMER DRUG ADVERTISING. 
6
The Federal Food, Drug, and Cosmetic Act (21 
7
U.S.C. 301 et seq.) is amended— 
8
(1) in section 301 (21 U.S.C. 331), by adding 
9
at the end the following: 
10
02:13 Aug 15, 2019
H4106
2 
•HR 4106 IH
‘‘(fff) The conduct of direct-to-consumer advertising 
1
of a drug in violation of section 506J.’’; and 
2
(2) in chapter V, by inserting after section 506I 
3
(21 U.S.C. 356f) the following: 
4
‘‘SEC. 506J. DIRECT-TO-CONSUMER DRUG ADVERTISING. 
5
‘‘(a) PROHIBITIONS.— 
6
‘‘(1) FIRST THREE YEARS.— 
7
‘‘(A) IN
GENERAL.—Subject to subpara-
8
graph (B), no person shall conduct direct-to- 
9
consumer advertising of a drug for which an 
10
application is submitted under section 505(b) 
11
before the end of the 3-year period beginning 
12
on the date of the approval of such application. 
13
‘‘(B) WAIVER.—The Secretary may waive 
14
the application of subparagraph (A) to a drug 
15
during the third year of the 3-year period de-
16
scribed in such subparagraph if— 
17
‘‘(i) the sponsor of the drug submits 
18
an application to the Secretary pursuant to 
19
subparagraph (C); and 
20
‘‘(ii) the Secretary, after considering 
21
the application and any accompanying ma-
22
terials, determines that direct-to-consumer 
23
advertising of the drug would have an af-
24
firmative value to public health. 
25
02:13 Aug 15, 2019
H4106
3 
•HR 4106 IH
‘‘(C) APPLICATION FOR WAIVER.—To seek 
1
a waiver under subparagraph (B), the sponsor 
2
of a drug shall submit an application to the 
3
Secretary at such time, in such manner, and 
4
containing such information as the Secretary 
5
may require. 
6
‘‘(2) SUBSEQUENT YEARS.—The Secretary may 
7
prohibit direct-to-consumer advertising of a drug 
8
during the period beginning at the end of the 3-year 
9
period described in paragraph (1)(A) if the Sec-
10
retary determines that the drug has significant ad-
11
verse health effects based on post-approval studies, 
12
risk-benefit analyses, adverse event reports, the sci-
13
entific literature, any clinical or observational stud-
14
ies, or any other appropriate resource. 
15
‘‘(b) REGULATIONS.—Not later than 1 year after the 
16
date of the enactment of this section, the Secretary shall 
17
revise the regulations promulgated under this Act gov-
18
erning drug advertisements to the extent necessary to im-
19
plement this section. 
20
‘‘(c) RULE OF CONSTRUCTION.—This section shall 
21
not be construed to diminish the authority of the Secretary 
22
to prohibit or regulate direct-to-consumer advertising of 
23
drugs under other provisions of law. 
24
02:13 Aug 15, 2019
H4106
4 
•HR 4106 IH
‘‘(d) EFFECTIVE DATE.—This section applies only 
1
with respect to a drug for which an application submitted 
2
under section 505(b) is approved on or after the date that 
3
is 1 year before the date of the enactment of this section.’’. 
4
Æ 
02:13 Aug 15, 2019
H4106
